吡咯烷-1-羰酰亚胺盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 吡咯烷-1-羰酰亚胺盐酸盐
• 英文名称: pyrrolidine-1-carboximidamide hydroiodide
• 英文别名: Pyrrolidin-1-ium-1-ylidenemethanediamine;iodide；pyrrolidin-1-ium-1-ylidenemethanediamine;iodide
• 化学式: C₅H₁₁N₃*HI
• 分子量: 241.075
• InChiKey: XPASGQSDLPDWNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  53.1
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  吡咯烷-1-羰酰亚胺盐酸盐 、 sodium (Z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 6-oxo-2-(pyrrolidin-1-yl)-1,6-dihydropyrimidine-4-carboxylic acid
  参考文献：
  名称：

  [EN] PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS
  [FR] COMPOSÉS DE PYRIMIDINONE AMIDE EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及嘧啶酮酰胺化合物，可能作为治疗中枢神经系统和/或与磷酸二酯酶2（PDE2）相关的外周障碍的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病、阿尔茨海默病、认知障碍、焦虑、抑郁症、偏头痛或亨廷顿病、帕金森病、帕金森病痴呆（PDD）和与纹状体功能不足或基底神经节功能障碍相关的其他疾病。

  公开号：

  WO2016186888A1

文献信息

• PHENYLTHIAZOLES AND USES THEREOF
  申请人：Purdue Research Foundation

  公开号：US20180319784A1

  公开（公告）日：2018-11-08

  Series of 2-phenyl-4-methylthiazole analogues are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant Straphylococcus aureus (MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.

  一系列2-苯基-4-甲基噻唑类似物被披露为治疗细菌感染，特别是耐甲氧西林金黄色葡萄球菌（MRSA）相关感染的潜在治疗药物。还声明了一种治疗MRSA相关感染的方法。
• Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity
  作者：Ahmed Kotb、Nader S. Abutaleb、Mohamed A. Seleem、Mohamed Hagras、Haroon Mohammad、Ashraf Bayoumi、Adel Ghiaty、Mohamed N. Seleem、Abdelrahman S. Mayhoub

  DOI：10.1016/j.ejmech.2018.03.044

  日期：2018.5

  A new series of phenylthiazoles with t-butyl lipophilic component was synthesized and their antibacterial activity against a panel of multidrug-resistant bacterial pathogens was evaluated. Five compounds demonstrated promising antibacterial activity against methicillin-resistant staphylococcal strains and several vancomycin-resistant staphylococcal and enterococcal species. Additionally, three derivatives 19, 23 and 26 exhibited rapid bactericidal activity, and remarkable ability to disrupt mature biofilm produced by MRSA USA300. More importantly, a resistant mutant to 19 couldn't be isolated after subjecting MRSA to sub-lethal doses for 14 days. Lastly, this new series of phenylthiazoles possesses an advantageous attribute over the first-generation compounds in their stability to hepatic metabolism, with a biological half-life of more than 9 h. (C) 2018 Elsevier Masson SAS. All rights reserved.